Uncomplicated malaria as a risk factor for COVID-19 duration and severity in western Kenya and Burkina Faso (MALCOV): a prospective cohort study
BACKGROUND: The relationship between malaria and COVID-19 varies across different clinical scenarios; historical malaria exposure might protect against severe COVID-19, whereas co-infection in hospitalised patients with severe disease might increase mortality. Interactions between non-severe malaria and COVID-19 remain poorly understood. We conducted a cohort study among COVID-19 patients of all ages in western Kenya and Burkina Faso to assess the effects of acute, uncomplicated Plasmodium falciparum malaria co-infection on COVID-19 outcomes in ambulatory patients. METHODS: Participants with laboratory-confirmed SARS-CoV-2 infection (positive rapid antigen test or reverse transcription quantitative real-time PCR [RT-qPCR]) were tested for malaria by rapid antigen tests with confirmatory microscopy. Patients with COVID-19 and malaria co-infection received artemether-lumefantrine or pyronaridine-artesunate. COVID-19 symptom course was assessed daily using FLU-PRO Plus (a validated patient-reported outcome instrument) until day 14. Viral load was measured by RT-qPCR on days 0, 3, 7, 14, and 28. The primary endpoint was time to symptom resolution on the FLU-PRO Plus. Analyses were adjusted for country, age, disease severity, and viral load. FINDINGS: =0·042). SARS-CoV-2 clearance was slower in the malaria group by day 7 (aHR 0·69 [95% CI 0·51-0·94]; p=0·017) but was similar between groups by day 28 (adjusted risk ratio 0·99 [95% CI 0·79-1·24]; p=0·95). INTERPRETATION: This study shows that acute uncomplicated malaria co-infection does not adversely affect COVID-19 progression when appropriately treated. Moreover, serological evidence confirms that previous lifelong malaria exposure might provide some protection, with exposed individuals having faster symptom resolution. FUNDING: Gates Foundation. TRANSLATION: For the French translation of the abstract see Supplementary Materials section.
Authors
- Alphonse Ouédraogo (ORCID: https://orcid.org/0000-0002-3520-6637)
- Julian Matthewman (ORCID: https://orcid.org/0000-0003-3291-2381)
- Everlyne Delylah Ondieki (ORCID: https://orcid.org/0000-0003-3756-7644)
- Tegwen Marlais (ORCID: https://orcid.org/0000-0003-0955-9807)
- Maia Lesosky (ORCID: https://orcid.org/0000-0002-2026-958X)
- Issiaka Soulama (ORCID: https://orcid.org/0000-0002-0993-0525)
- Aïssata Barry (ORCID: https://orcid.org/0000-0001-5338-3728)
- Emilie S. Badoum (ORCID: https://orcid.org/0000-0001-5993-7402)
- Jennifer Canizales
- David J. Allen (ORCID: https://orcid.org/0000-0002-1194-0415)
- Hellen C. Barsosio (ORCID: https://orcid.org/0000-0002-0261-9814)
- Ben Idriss Soulama
- Brian Tangara
- Morine Achieng
- Helena Brazal-Monzó
- Anna Drabko
- Luke Hannan (ORCID: https://orcid.org/0000-0002-8217-843X)
- Telesphorus Odawo
- Miriam Wanjiku
- Henry Aura
- Sodiomon B. Sirima
- Jean Moïse T Kaboré
- Chris Drakeley
- Alfred B Tiono
- Samuel S Serme
- Kevin K A Tetteh
- William Wu
- Kephas Otieno
- Eric D Onyango
- Simon Kariuki
- Feiko O ter Kuile
Institutions
- University of London (GB)
- Liverpool School of Tropical Medicine (GB)
- Kenya Medical Research Institute (KE)
- London School of Hygiene & Tropical Medicine (GB)
- Quantitative BioSciences (US)
- Lung Institute (US)
- Groupe de Recherche et d’Action sur le Foncier (BF)
- Institut de Recherche en Sciences de la Santé (BF)
Publication Details
- Journal
- The Lancet Global Health
- Published
- 2026-04-15
- DOI
- https://doi.org/10.1016/s2214-109x(25)00541-8
- Primary Topic
- Malaria Research and Control
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bill and Melinda Gates Foundation